Vandetanib - AstraZeneca

Drug Profile

Vandetanib - AstraZeneca

Alternative Names: AZD 6474; Caprelsa; SAR 390530; Zactima; ZD 6474; Zictifa

Latest Information Update: 31 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Fox Chase Cancer Center; Hoosier Cancer Research Network; Sanofi; University of Oxford
  • Class Antineoplastics; Bromobenzenes; Fluorobenzenes; Piperidines; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thyroid cancer
  • Phase II Malignant melanoma; Small cell lung cancer
  • No development reported Brain metastases; Gastrointestinal cancer
  • Discontinued Biliary cancer; Breast cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Malignant pleural effusion; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 10 May 2018 AstraZeneca suspends patient enrolment in the phase II ZACFAST trial due to drugs unavailable for Breast cancer in USA (PO) (NCT01934335)
  • 09 Dec 2017 AstraZeneca re-initiates the phase III VERIFY trial for Thyroid cancer (Late-stage disease) in USA, Brazil, China, Japan, Russia, Denmark, France, Italy, Poland, Spain, Czechia and Sweden (PO) (NCT01876784)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top